Gene Bio Tech진바이오텍

Gene Bio Tech reports steady profitability on a modest margin, with the stock up 22.6% over the past year.

Gene Bio Tech makes functional feed additives and animal medicines for livestock and pet food producers in Korea and export markets. For the twelve months to H1 2026 it reported revenue of about ₩89.3B, operating income of about ₩4.5B and net income of about ₩3.7B, with a 5.1% operating margin. At ₩4,990 the shares trade at roughly 11.7 times earnings and 0.8 times book value, with a market value of about ₩43.0B.

What stands out

• Revenue has grown from about ₩79.5B in 2023 to about ₩90.8B in 2025, though 2025 growth of 9.4% came after a 4.4% rise in 2024.
• Operating margin has been thin, at 4.3% in 2025 and 5.1% on a trailing basis, compared with 2% in 2022 and a loss in 2021.
• Net income of ₩3.8B in 2025 was higher than operating income of ₩3.9B minus a small gap, supported by the trailing net margin of 4.1%.
• Cash of about ₩9.2B is reported against no listed borrowings, and liabilities equal 42.7% of equity.
• Free cash flow for the trailing period was about ₩4.5B, and the company has filed a cash dividend decision with a dividend yield of about 1%.

What to watch

• The cash dividend decision and its amendment filed on 14 October 2026, including the interim dividend record date, have not been detailed in the data provided.
• Foreign ownership fell from 3.3% to 2.2% over 60 days and retail and foreign investors were net sellers over the last 20 days, so investor flows bear watching.
• The next quarterly or annual results were not given in the data; the company's filings show a half-year report for June 2026 already filed in August.